New post hoc and pooled analyses from the OASIS 4 trial presented at ObesityWeek 2025 show that oral semaglutide 25 mg improves glycemic control, cardiovascular risk factors, and weight outcomes ...

ORLANDO -- Long-term results from trials of new drugs for hereditary angioedema (HAE) continue to support efficacy and safety ...

Imneskibart will now enter late-stage trials after the drug offered durable tumour shrinkage in NSCLC, melanoma and other ...

Developed by British drugmaker GSK, RTS,S/AS01E in 2021 became the first malaria vaccine to be recommended by the World ...

Akebia Therapeutics shares retreated Monday after the company dropped plans for a Phase 3 clinical trial of its drug Vafseo for certain patients. Shares were trading at $1.66, down 19% and nearing the ...

Eli Lilly has shared positive results from a Phase II clinical trial (NCT06230523) evaluating eloralintide, an investigational once-weekly, selective amylin receptor, in adults with obesity or ...

Current treatment options have been limited to symptom control. Telitacicept, a novel fusion protein, and ianalumab, a monoclonal antibody, demonstrate improvement in disease activity.

Trial achieved biological proof-of-concept, dose discovery and biomarker improvement. San Diego, California--(Newsfile Corp. - November 4, 2025) - Thiogenesis Therapeutics, Corp.

Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

An update from Psyence Biomedical ( ($PBM) ) is now available. Psyence Biomedical Ltd. recently appointed its Chief Financial Officer, Mr. Warwick ...

Get the latest on Corvus Pharmaceuticals’ Q3 2025 earnings, soquelitinib trial updates, and strategic outlook.